RxDoctor Payments Data

Angela Smith

Family · Lebanon, OHNPI 1669921771

Payments from drug & device makers

$2,536in general payments, 2019–2025

Across 82 payments — averaging $30.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Relievant Medsystems, Inc.$621
  • Collegium Pharmaceutical, Inc.$321
  • AbbVie$305
  • Neurocrine Biosciences, Inc.$151
  • Boston Scientific$144
  • Urovant Sciences Inc$130
  • plus $864 from 14 others

What the payments were for

  • Travel & lodging$37115%
  • Food & beverage$2,16585%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,536 in reported general payments places this provider in the 85th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$138,141
Medicare patients
369
Services billed
1,495

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate42$26,627
OxycontinOxycodone Hcl15$11,364
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen349$8,632
EliquisApixaban15$8,331
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen304$6,197
GemtesaVibegron20$5,913
Lidocaine49$5,745
Pregabalin93$3,544
Gabapentin288$3,488
Morphine Sulfate ErMorphine Sulfate56$2,637
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$2,423
Buprenorphine11$2,136
Diclofenac Sodium105$1,890
Ondansetron Hcl14$1,452
Tizanidine Hcl132$1,300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$321$26,62742 claims
PfizerEliquis$113$8,33115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,812 family providers in Ohio.

Other family in Lebanon

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →